Go back

Ketamine’s Role for Discontinuing Long-Term Benzodiazepine Use for Treatment-Resistant Depression

In the complex landscape of depression treatment, benzodiazepines, such as Xanax and Klonopin, often play a significant role in treatment strategies, with 30–50% of patients being prescribed these medications at some point. While guidelines recommend short-term usage of benzodiazepines, 10–15% of individuals with depression, especially those facing treatment-resistant depression, end up relying on them long term. However, chronic benzodiazepine use comes with a host of risks, from increased accidents to cognitive impairment and potential elevated rates of mortality. Unsurprisingly, attempts to discontinue benzodiazepines pose clinical challenges due to distressing withdrawal symptoms such as anxiety, insomnia, and increased suicidality resulting from a potential rebound effect.

A recent study explores the use of low-dose intravenous ketamine to facilitate long-term benzodiazepine discontinuation in patients with active and severe treatment-resistant depression. Let’s delve into the potential benefits and challenges of this innovative intervention, shedding light on a promising avenue in the pursuit of improved mental health and treatment for depression.

What are Benzodiazepines and Their Associated Risks

Benzodiazepines are a class of psychoactive drugs commonly prescribed for various medical conditions, including anxiety, insomnia, and seizure disorders. Benzodiazepines work by enhancing the activity of the neurotransmitter gamma-aminobutyric acid (GABA) in the central nervous system. The overall effect is a calming or sedative influence, making benzodiazepines potentially effective in treating various conditions. However, it's important to note that their use is intended for short-term, rather than long-term, purposes. While they may be effective in managing these conditions, there are also risks associated with their use. It is important to note that individual responses to benzodiazepines can vary, and the following list highlights potential risks and side effects:

  • Dependence and Withdrawal: Benzodiazepines can be habit-forming, leading to physical and psychological dependence. Long-term use or abrupt discontinuation can result in withdrawal symptoms such as anxiety, insomnia, irritability, and seizures.
  • Tolerance: With prolonged use, individuals may develop tolerance, meaning that over time, higher doses are needed to achieve the same therapeutic effect. This can increase the risk of dependence, abuse, and other adverse effects.
  • Cognitive Impairment: Benzodiazepines can cause drowsiness, sedation, and cognitive impairment. This may affect memory, attention, and reaction times, posing risks, especially when operating machinery or driving. Some studies suggest that long-term use of benzodiazepines may be associated with cognitive decline, particularly in older adults.
  • Risk of Falls and Injuries: Elderly individuals are particularly vulnerable to the sedative effects of benzodiazepines, which can increase the risk of falls and injuries.
  • Respiratory Depression: At high doses or when combined with other central nervous system depressants (e.g., alcohol), benzodiazepines can lead to respiratory depression, which is a slowing of breathing. This is a serious concern, especially in cases of overdose.
  • Paradoxical Reactions: In some cases, benzodiazepines may cause paradoxical reactions, leading to increased anxiety, agitation, or aggression. This is more common in certain populations, such as the elderly. Additionally, discontinuing benzodiazepines abruptly can lead to rebound symptoms, including a temporary increase in the severity of the symptoms the medication was initially prescribed to treat.

Study Design and Results

This study aimed to assess the feasibility and impact of ketamine as an intervention for discontinuation of their benzodiazepine prescription in treatment-resistant depression patients. The primary goal was to determine the percentage of individuals achieving complete abstinence from benzodiazepines post-ketamine treatment. Involving fifty patients, 44% of whom were chronic benzodiazepine users, the study revealed that after a six-session ketamine intervention, 91% successfully discontinued benzodiazepines. 64% remained benzodiazepine-free over a 12-month follow-up, with significant improvements in depression, anxiety, and suicidality observed. Overall, the findings suggest that ketamine can effectively lead to benzodiazepine discontinuation in some patients, positively impacting depressive symptoms and overall tolerability.

Final Thoughts

I frequently receive feedback from my patients expressing frustration with their prescription medications, including benzodiazepines. They are troubled by the side effects and often question the long-term effectiveness of these medications. The study highlights the success of using ketamine to discontinue chronic benzodiazepines in challenging cases. Despite limitations such as a small sample size, the findings suggest a unique opportunity for medication changes with ketamine, emphasizing its potential benefits in alleviating depressive symptoms and managing withdrawal states. While further research, including controlled trials, is warranted to explore this application rigorously, this offers promise for many individuals who desire or struggle to come off psychoactive medications.

Keep reading

Disclaimer: All content on this website, including (but not limited to) this statement, news, blog post, article, testimonial, or FAQ is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can do that. Therefore, we cannot be responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to the Terms & Conditions for more information.